- Home
- NUVL vs SOUN Comparison
NUVL vs SOUN Comparison
Compare NUVL & SOUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- SOUN
- Stock Information
- Founded
- NUVL 2017
- SOUN 2005
- Country
- NUVL United States
- SOUN United States
- Employees
- NUVL N/A
- SOUN N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- SOUN EDP Services
- Sector
- NUVL Health Care
- SOUN Technology
- Exchange
- NUVL Nasdaq
- SOUN Nasdaq
- Market Cap
- NUVL 6.5B
- SOUN 5.2B
- IPO Year
- NUVL 2021
- SOUN N/A
- Fundamental
- Price
- NUVL $104.59
- SOUN $17.85
- Analyst Decision
- NUVL Strong Buy
- SOUN Buy
- Analyst Count
- NUVL 11
- SOUN 7
- Target Price
- NUVL $121.45
- SOUN $15.83
- AVG Volume (30 Days)
- NUVL 498.8K
- SOUN 50.3M
- Earning Date
- NUVL 11-10-2025
- SOUN 11-06-2025
- Dividend Yield
- NUVL N/A
- SOUN N/A
- EPS Growth
- NUVL N/A
- SOUN N/A
- EPS
- NUVL N/A
- SOUN N/A
- Revenue
- NUVL N/A
- SOUN $131,449,000.00
- Revenue This Year
- NUVL N/A
- SOUN $99.96
- Revenue Next Year
- NUVL N/A
- SOUN $28.92
- P/E Ratio
- NUVL N/A
- SOUN N/A
- Revenue Growth
- NUVL N/A
- SOUN 136.97
- 52 Week Low
- NUVL $55.54
- SOUN $4.97
- 52 Week High
- NUVL $103.69
- SOUN $24.98
- Technical
- Relative Strength Index (RSI)
- NUVL 71.49
- SOUN 50.43
- Support Level
- NUVL $90.00
- SOUN $17.35
- Resistance Level
- NUVL $99.94
- SOUN $19.09
- Average True Range (ATR)
- NUVL 4.59
- SOUN 1.41
- MACD
- NUVL 1.10
- SOUN -0.33
- Stochastic Oscillator
- NUVL 100.00
- SOUN 22.99
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About SOUN SoundHound AI Inc
SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.